About MabCure Inc.

In spite of major advances over the past 20 years, cancer remains one of the most deadly diseases with unimpressive "cure" rates. The billions of dollars spent over the past few decades have led to only modest gains in the fight against cancer.  Effective treatment of most cancers is limited by the toxic effects of chemotherapy, radiotherapy, or antibody-based drugs which are not cancer-specific. There is a clear need for developing a new strategy against incurable cancers.  One possible approach is to develop means for more effective diagnosis of early stage cancer; the other is to create more potent and specific drugs against advanced cancer.

Early Detection of Cancer

Most “killer” cancers such as ovarian, colorectal, breast, lung, and prostate carcinomas owe their lethality to late diagnosis when the disease has already spread beyond its original site. 
According to the American Cancer Society, most patients have more than a 90% chance of 5-year survival when cancer is detected early. The only example of an effective early detection test is the PAP smear which has brought about a significant reduction in cervical cancer morbidity and mortality. However, similar methods for screening and diagnosing most cancers in their early stage remain elusive.

MabCure Strategy

MabCure is a company whose vision is to change the perception of cancer as a largely incurable disease. MabCure's scientists believe that the key to early detection of cancer by antibodies lies in their ability to identify putative tumor markers or tumor-specific antigens (TSA), present on the surface of these cells. Using its proprietary technology, MabCure has created unique and highly specific Mabs against several cancers (e.g. ovarian and prostate carcinomas) which could potentially identify these diseases in their earliest stage. The development of unique and highly specific diagnostic tests could lead to far earlier diagnoses than has ever been possible which, in turn, will bring curing cancers closer to clinical reality.
Beyond the initial focus on developing diagnostic tests, MabCure’s strategic plan calls for the application of its proprietary cancer-specific Mabs in three additional areas:

1. The imaging of cancer
2. Immunotherapy of cancer
3. Discovery of novel cancer markers (tumor specific antigens), which can lead to the development of potent anti-cancer drugs.

In summary, MabCure’s first goal is the development of simple diagnostic tests for the early detection of ovarian, prostate, colorectal and breast carcinomas. Each test will be based upon specific Mabs against a given cancer which should be able to detect unique cancer markers in the blood, urine or other body fluids.   Identifying the presence of disease before it disseminates beyond its original site should lead to a 90% cure rate of these cancer patients.

MANAGEMENT

Dr. Amnon Gonenne, President & CEO
Dr. Eli Orr, Executive Vice President and Chief Scientific Officer
Mr. Ron Kalfus, CPA, Chief Financial Officer

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on MabCure. This information is not represented to be a complete description and is subject to change without notice. MabCure may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.